- AU$267.82m
- AU$236.45m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.23 | ||
| Price to Tang. Book | 8.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -140.35% | ||
| Return on Equity | -100.19% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | n/a | n/a | n/a | 4.55 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Directors
- Paul Hopper CHM (64)
- Leslie Chong CEO
- Nicholas Ede CTO
- Steven Cha OTH
- Monil Shah OTH
- Phillip Hains SEC
- Nathan Jong SEC
- Jens Eckstein NED
- Lesley Russell NID (60)
- Charles Walker NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 30th, 1986
- Public Since
- December 2nd, 1993
- No. of Shareholders
- 29,478
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 7,439,399,758
- Address
- Suite 12.01, Level 12, Bligh House,4-6 B, SYDNEY, 2000
- Web
- https://www.imugene.com/
- Phone
- +61 398245254
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for IMU
Similar to IMU
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Imugene share price?
As of Today at 02:16 UTC, shares in Imugene are trading at AU$0.04. This share price information is delayed by 15 minutes.
How has the Imugene share price performed this year?
Shares in Imugene last closed at AU$0.04 and the price had moved by -70% over the past 365 days. In terms of relative price strength the Imugene share price has underperformed the ASX All Ordinaries Index by -70.15% over the past year.
What are the analyst and broker recommendations for Imugene?
The overall consensus recommendation for Imugene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Imugene dividend yield?
Imugene does not currently pay a dividend.
Does Imugene pay a dividend?
Imugene does not currently pay a dividend.
When does Imugene next pay dividends?
Imugene does not currently pay a dividend.
How do I buy Imugene shares?
To buy shares in Imugene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Imugene?
As of the previous close price of AU$0.04, shares in Imugene had a market capitalisation of AU$267.82m.
Where are Imugene shares listed?
Here are the trading details for Imugene:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IMU
What kind of share is Imugene?
Based on an overall assessment of its quality, value and momentum Imugene is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Imugene share price forecast for 2025?
The analyst consensus target price for shares in Imugene is AU$0.28. That is 663.89% above the last closing price of AU$0.04.
Analysts covering Imugene currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
Find out moreWhat is the trend in the Imugene share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Imugene. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -26.52%.
As of the last closing price of AU$0.04, shares in Imugene were trading -23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Imugene PE Ratio?
The Imugene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Imugene?
Imugene's management team is headed by:
- Paul Hopper - CHM
- Leslie Chong - CEO
- Nicholas Ede - CTO
- Steven Cha - OTH
- Monil Shah - OTH
- Phillip Hains - SEC
- Nathan Jong - SEC
- Jens Eckstein - NED
- Lesley Russell - NID
- Charles Walker - NID